Cardiovascular

TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?

November 6, 2007
Gregg Stone
Gregg Stone
REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone presented data from the TAXUS DES trials which looked at patients surviving more than a year after receiving either paclitaxel-eluting or bare metal stents. After his talk at the American Heart Association he discussed his findings with Sarah Maxwell.

Download this interview

Add podcast to iTunes

Similar Interviews

  • Audio Journal of Cardiovascular Medicine: Sirolimus-Eluting Better Than Uncoated Stents for Primary Angioplasty

    • CHRISTIAN SPAULDING, Cochin Hospital, Paris REFERENCE: N Engl J Med 2006;355:1093, 1105,1169 Two leading articles in the same edition of the New

  • Late-Stent Throbosis Risk after Clopidogrel Withdrawal: Greater in Drug Eluting Stents

    • Matthias Pfisterer, University Hospital Basel American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta. Abstract Number: 422-11. Lancet 2005:366:921 Clopidogrel

  • Bioabsorbable Everolimus-Eluting Stent: 6-Month Angiographic and IVUS Results

    • Patrick Serruys Spencer King PATRICK SERRUYS, Erasmus University, Rotterdam COMMENT: SPENCER KING, Piedmont Hospital, Atlanta REFERENCE: Abstract 2402-3, American College of Cardiology New Orleans Six-months

    Post a comment